Skip to Main content Skip to Navigation
Journal articles


Abstract : Biopharmaceuticals are primarily therapeutic proteins developed to perform specific functions by acting on the disease pathophysiology. Compared with low-molecular chemically synthesized drugs, production of biopharmaceuticals is much more complex and routes of administration and pharmacokinetics differ. Biopharmaceuticals are blockbusters in the treatment of inflammatory diseases, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases, and the introduction of these drugs has revolutionized treatment. Disadvantages include their high costs and the fact that they can evoke antidrug antibodies leading to decreased efficacy. Treatment can be optimized through the development of dosing algorithms and cost can be reduced by biosimilars, after a comparable biological activity, safety, and efficacy have been demonstrated.
Complete list of metadata
Contributor : Denis Mulleman Connect in order to contact the contributor
Submitted on : Monday, January 14, 2019 - 4:14:56 PM
Last modification on : Tuesday, January 11, 2022 - 5:56:10 PM




Ann Gils, Antonio Bertolotto, Denis Mulleman, Theodora Bejan-Angoulvant, Paul Declerck. Biopharmaceuticals. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2017, 39 (4), pp.308-315. ⟨10.1097/FTD.0000000000000385⟩. ⟨hal-01980742⟩



Record views